Intentar ORO - Gratis
Time to build Indian Medtech industry to global reckoning
Bio Spectrum
|May 2020
India has built amazing infrastructure of science especially interdisciplinary and translational aspects of biology in the last 15 years despite history of low level of investments both in R&D (0.8 per cent of the GDP) as well as healthcare (1.3 per cent of the GDP). This needs to change not just as a stopgap measure but greater investment, consistently over a longerrange horizon, is important. And there is need to leverage the strengths and find strategic responses to the gaps in a mission mode.
-
Over the last decade there has been a major push to develop homegrown medtech product startups in healthcare and other areas of biotech. Several agencies notably Department of Science & Technology (DST), Department of Biotechnology- Biotechnology Industry Research Assistance Council (DBT-BIRAC), Millennium Alliance, Indo-U.S. Science and Technology Forum (IUSSTF), Atal Innovation Mission (AIM)-Niti Aayog and others have contributed to injecting funding and other support mechanisms to build 3000- 4000 biotech/medtechstartups as well as 200 S&T incubators in the country.
This arguably is a national portfolio that has been built through taxpayer's money and painstaking efforts of various stakeholders, most notably the leadership shown by incubators. The incubators housing them are analogous to an “asset house”.
The innovation community has responded with a can-do attitude and have scrambled to kick start COVID-19 focused solutions. The Principal Scientific Adviser’s (PSA) Office has constituted several task forces that are co-ordinating different aspects of the response with speed and precision.

COVID-19 Funding: Fast decisions
Most Science & Technology arms of the Government of India have launched COVID-19 specific funding calls, be it CAWACH by DST, Council of Scientific and Industrial Research (CSIR) labs, DBT-BIRAC (a special COVID-19 call), Technology Development Board (TDB) and Invest India as well as big incubators such as IKP Knowledge Park (IKP), Venture Center, SINE-IIT Bombay, Centre for Cellular and Molecular Platforms (C-CAMP), SIIC- IIT Kanpur, AIC-CCMB and FITT-IIT Delhi amongst others.
Esta historia es de la edición May 2020 de Bio Spectrum.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE Bio Spectrum
Bio Spectrum
Molbio announces collaboration with UE LifeSciences to expand iBreastExam globally
Molbio Diagnostics, a Goa-based point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies, and UE LifeSciences, a Philadelphia-based innovator engaged in the business of developing and manufacturing health technology solutions, with a primary focus on enabling early cancer detection technologies, have announced an exclusive collaboration, seeking to make early breast cancer detection accessible to millions of women in over 50 countries across the developing world.
1 min
November 2025
Bio Spectrum
CRO Reforms: Tilting Scale towards Accelerated Growth & Transparency
India's clinical research ecosystem is undergoing a major transformation, driven by a wave of regulatory reforms and rapid market expansion.
10 mins
November 2025
Bio Spectrum
When Spectra Speak: Letting AI Read the Fine Print of Biologics
Biologic characterisation has historically relied heavily on spectroscopy, which transforms chemical complexity into comprehensible fingerprints. Through the careful use of AI, supported by strict data procedures and scientific supervision, these fingerprints may be read more quickly & thoroughly.
5 mins
November 2025
Bio Spectrum
Working on our supply chain to set benchmarks in quality and further enhance India's position as a trusted clinical research supplier on a global scale
Abdos Lifesciences, which is committed to enabling science to thrive by delivering precision-engineered, high-performance laboratory consumables and instruments that meet the highest global standards, manufactures over 400 products across 12+ categories in automated cleanroom environments certified under ISO and CE-IVDR standards, ensuring sterility, traceability, and consistency crucial for decentralised and global clinical trials. Each product is barcoded, tamper-proof, and supported by easily accessible documentation such as Certificates of Analysis (COA), Technical Data Sheets (TDS). With a presence in more than 90 countries, Abdos Lifesciences ensures researchers worldwide receive reliable products and dedicated support, empowering science to advance seamlessly across borders and timelines. In an interview with BioSpectrum India Shrey Agarwal, CEO & Director, Abdos Lifesciences spoke to many issues including how the company is ensuring compliance with evolving global standards for products used in regulated clinical environments. Edited excerpts;
4 mins
November 2025
Bio Spectrum
Gene Solutions and AMPATH launch advanced genomics laboratory in Hyderabad
Gene Solutions, a leading genetic testing innovator in Asia, has partnered with AMPATH (American Institute of Pathology and Laboratory Sciences), a trusted provider of high-quality diagnostic services in India, to open a new advanced genomics laboratory in Hyderabad.
1 min
November 2025
Bio Spectrum
Patient Consent - How is it different under medical ethics and data protection?
In the ethical and legal framework of medicine and law, consent has always existed. Within healthcare, it signifies the individual's right to be informed and to choose. However, in the digital era, consent assumes a broader function; it becomes the foundation for lawful processing of personal data. For the pharma and clinical-research sectors, this distinction carries significant implications. The Digital Personal Data Protection Act, 2023 (DPDPA), has redefined how personal and health-related data must be managed. This article explores why consent under data-protection law differs from medical consent, drawing lessons from the irregularities uncovered in the Ahmedabad clinical trials, and outlines the emerging compliance responsibilities under the DPDPA.
3 mins
November 2025
Bio Spectrum
We aim to make bio-based industries a key pillar of the state's GSDP by 2030: Kerala CM
Kerala recently set the spotlight on its growing life sciences ecosystem with Bio Connect 3.0 – International Life Sciences Conclave & Expo, held on October 9 & 10, 2025, in Thiruvananthapuram.
3 mins
November 2025
Bio Spectrum
DBT inks pact with Uttar Pradesh to boost biotech, pharma and medtech innovation
An official Memorandum of Understanding (MoU) has been signed between the Department of Biotechnology (DBT), Government of India and the Government of Uttar Pradesh.
1 min
November 2025
Bio Spectrum
Abbott launches world's first dual-chamber leadless pacemaker system in India
Abbott, a global healthcare company, has announced the launch of AVEIR dual chamber (DR) leadless pacemaker system - the first of its kind in the world.
1 min
November 2025
Bio Spectrum
Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr
Delhi-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).
1 min
November 2025
Translate
Change font size
